AI in Drug Discovery Market By Component (Software, Services), By Technology (Machine Learning, Deep Learning, Natural Language Processing), By Application (Target Identification, Molecule Screening, Lead Optimization, Preclinical Testing, Clinical Trials), By Therapeutic Area (Oncology, Neurodegenerative Diseases, Cardiovascular Diseases, Metabolic Diseases, Infectious Diseases), By End User, By Region, And Segment Forecast, 2026-2033

Report ID: SQMIG35G2344 | Region: Global | Published Date: August, 2025
Pages: 192 |Tables: 149 |Figures: 78

To request a free sample copy of this report, please complete the form below.

Our Clients

Schineder Electric

KSIA - Korea Semiconductor Industry Association

Hitachi Astemo Limited

Samsung Electronics

Halvo holdings

NTT corporation

AGC Inc

Siemens AG

Unilever

Merck Pharmaceuticals

Atlas Copco

Hologic - Medical Technology company

Novartis

Henkel

Reckitt

Schineder Electric

KSIA - Korea Semiconductor Industry Association

Hitachi Astemo Limited

Samsung Electronics

Halvo holdings

NTT corporation

AGC Inc

Siemens AG

Unilever

Merck Pharmaceuticals

Atlas Copco

Hologic - Medical Technology company

Novartis

Henkel

Reckitt

FAQs

Global AI in Drug Discovery Market size was valued at USD 1.82 Billion in 2024 and is poised to grow from USD 2.34 Billion in 2025 to USD 17.43 Billion by 2033, growing at a CAGR of 28.5% during the forecast period (2026–2033).

Key vendors in the AI in Drug Discovery Market include IBM, NVIDIA, BenevolentAI, Exscientia, Schrödinger, Insilico Medicine, Atomwise, Recursion Pharmaceuticals, Google DeepMind, and Microsoft. These companies focus on AI-driven drug development, molecular modeling, clinical research optimization, and accelerating pharmaceutical discovery processes through advanced machine learning technologies.

The key driver of the AI in Drug Discovery Market is the growing need to accelerate drug development while reducing research costs and timelines. Increasing adoption of artificial intelligence for predictive analytics, molecular modeling, and clinical trial optimization, along with rising pharmaceutical R&D investments, is significantly driving market growth globally.

The key market trend in the AI in Drug Discovery Market is the increasing integration of machine learning and deep learning technologies in drug development processes. Growing collaborations between pharmaceutical and AI companies, rising adoption of cloud-based platforms, and advancements in predictive analytics are accelerating precision medicine and therapeutic discovery globally.

North America accounted for the largest share in the AI in Drug Discovery Market due to strong pharmaceutical research infrastructure, high adoption of advanced AI technologies, and significant investments in healthcare innovation. The presence of leading biotechnology and technology companies, along with supportive government initiatives, further drives regional market growth.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Luca Giovannini, Marketing Innovation Senior Manager, Trelleborg.

To request a free sample copy of this report, please complete the form below.

Our Clients

FAQs

What is the global market size of AI in Drug Discovery Market?

Who are the key vendors in the AI in Drug Discovery Market?

What is the key driver of AI in Drug Discovery Market?

What is the key market trend for AI in Drug Discovery Market?

Which region accounted for the largest share in AI in Drug Discovery Market?

$5,300